Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells

References

• Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115:2618–2624.
   PubMed Web of Science ®Google Scholar
• Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23–34.
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Taverna P, et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011;118:693–702.
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Weaver M, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001;2:167–179.
   PubMedGoogle Scholar
• Amson R, Sigaux F, Przedborski S, et al. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989;86:8857–8861.
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Bearss D, et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150–4157.
   PubMed Web of Science ®Google Scholar
• Hogan C, Hutchison C, Marcar L, et al. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem 2008;283:18012–18023.
   PubMed Web of Science ®Google Scholar
• Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk lymphoma 2004;45:951–955.
   PubMed Web of Science ®Google Scholar
• Yang Q, Chen LS, Neelapu SS, et al. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 2012;120:3491–3500.
   PubMed Web of Science ®Google Scholar
• Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013;122:1610–1620.
   PubMed Web of Science ®Google Scholar
• Cervantes-Gomez F, Chen LS, Orlowski RZ, et al. Biological effects of the Pim Kinase Inhibitor, SGI-1776, in multiple myeloma. Clin Lymph Myelom Leuk 2013;13:S317–329.
   Google Scholar
• Aho TL, Sandholm J, Peltola KJ, et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43–49.
   PubMed Web of Science ®Google Scholar
• Macdonald A, Campbell DG, Toth R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006;7:1.
   PubMed Web of Science ®Google Scholar
• Li YY, Popivanova BK, Nagai Y, et al. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006;66:6741–6747.
   PubMed Web of Science ®Google Scholar
• Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358–45367.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Li X, et al. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008;27:4809–4819.
   PubMed Web of Science ®Google Scholar
• Zippo A, De Robertis A, Serafini R, et al. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007;9:932–944.
   PubMed Web of Science ®Google Scholar
• Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114:1618–1627.
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Mixter PF, et al. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim biophys Acta 2002;1593:45–55.
   PubMed Web of Science ®Google Scholar
• Morishita D, Katayama R, Sekimizu K, et al. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008;68:5076–5085.
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Kitanaka C, Noguchi K, et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999;274:18659–18666.
   PubMed Web of Science ®Google Scholar
• Bachmann M, Kosan C, Xing PX, et al. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006; 38:430–443.
   PubMed Web of Science ®Google Scholar
• Swords R, Kelly K, Carew J, et al. The Pim kinases: new targets for drug development. Curr Drug Targ 2011;12:2059–2066.
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379–3389.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008;111:3322–3330.
   PubMed Web of Science ®Google Scholar
• Mumenthaler SM, Ng PY, Hodge A, et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Therapeut 2009;8: 2882–2893.
   PubMed Web of Science ®Google Scholar
• Chen LS, Cortes JE, Gandhi V. Mechanisms of action of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia cells. Proc AACR. Washington, DC. April 6-10, 2013.
   Google Scholar
• Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2014;123:905–913.
   Google Scholar
• Xia Z, Knaak C, Ma J, et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009;52: 74–86.
   PubMed Web of Science ®Google Scholar
• Song JH, Kraft AS. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res 2012;72:294–303.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Burger JA, Wierda WG, et al. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149–153.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008;68:3413–3420.
   PubMed Web of Science ®Google Scholar
• Wei J, Stebbins JL, Kitada S, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010;53:4166–4176.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299–305.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–681.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–496.
   PubMed Web of Science ®Google Scholar
• Dai H, Li R, Wheeler T, et al. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 2005;65:276–286.
   PubMed Web of Science ®Google Scholar
• Chen WW, Chan DC, Donald C, et al. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443–451.
   PubMed Web of Science ®Google Scholar
• Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567–1576.
   PubMed Web of Science ®Google Scholar
• Placzek WJ, Wei J, Kitada S, et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010;1:e40.
   PubMed Web of Science ®Google Scholar
• Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and protein profiling suggest ABT-199 as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 2015; Epub ahead of print.
   Google Scholar
• Acton D, Domen J, Jacobs H, et al. Collaboration of pim-1 and bcl-2 in lymphomagenesis. Curr Top Microbiol Immunol 1992; 182:293–298
   PubMedGoogle Scholar